Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting
Bio-Techne (NASDAQ: TECH) announced advancements in its RNAscope technology for biomarker detection and pathology laboratory workflow improvements, to be presented at the 2025 USCAP Annual Meeting in Boston (March 22-27). The company's Advanced Cell Diagnostics brand will showcase the technology at booth #222.
During the 'RNAscope: Lightning Lunch and Learn' session on March 25, four leading pathologists will present their research:
- Dr. Rohit Mehra on TRIM63 mRNA as a marker in renal cell carcinoma
- Dr. Vikram Deshpande on albumin mRNA for liver tumors
- Dr. Brooke Howitt on point mutation detection in gynecologic tumors
- Dr. Gregory Bean on mRNA detection from CRTC1/3::MAML2 translocations
The presentations will demonstrate RNAscope's potential to improve performance over existing methods and reduce time to results in detecting clinically relevant biomarkers, including secreted proteins, point mutations, and chromosomal translocations.
Bio-Techne (NASDAQ: TECH) ha annunciato progressi nella sua tecnologia RNAscope per la rilevazione di biomarcatori e il miglioramento del flusso di lavoro nei laboratori di patologia, che saranno presentati al Congresso Annuale USCAP 2025 a Boston (22-27 marzo). Il marchio Advanced Cell Diagnostics dell'azienda mostrerà la tecnologia allo stand n. 222.
Durante la sessione 'RNAscope: Lightning Lunch and Learn' del 25 marzo, quattro importanti patologi presenteranno le loro ricerche:
- Dr. Rohit Mehra sul mRNA TRIM63 come marker nel carcinoma renale
- Dr. Vikram Deshpande sull'mRNA dell'albumina per i tumori epatici
- Dr. Brooke Howitt sulla rilevazione di mutazioni puntiformi nei tumori ginecologici
- Dr. Gregory Bean sulla rilevazione di mRNA da traslocazioni CRTC1/3::MAML2
Le presentazioni dimostreranno il potenziale di RNAscope di migliorare le prestazioni rispetto ai metodi esistenti e di ridurre i tempi per i risultati nella rilevazione di biomarcatori clinicamente rilevanti, inclusi proteine secrete, mutazioni puntiformi e traslocazioni cromosomiche.
Bio-Techne (NASDAQ: TECH) anunció avances en su tecnología RNAscope para la detección de biomarcadores y mejoras en el flujo de trabajo de los laboratorios de patología, que se presentarán en la Reunión Anual USCAP 2025 en Boston (22-27 de marzo). La marca Advanced Cell Diagnostics de la compañía mostrará la tecnología en el stand n.º 222.
Durante la sesión 'RNAscope: Lightning Lunch and Learn' el 25 de marzo, cuatro patólogos destacados presentarán sus investigaciones:
- Dr. Rohit Mehra sobre el mRNA TRIM63 como marcador en carcinoma de células renales
- Dr. Vikram Deshpande sobre el mRNA de albúmina para tumores hepáticos
- Dr. Brooke Howitt sobre la detección de mutaciones puntuales en tumores ginecológicos
- Dr. Gregory Bean sobre la detección de mRNA de translocaciones CRTC1/3::MAML2
Las presentaciones demostrarán el potencial de RNAscope para mejorar el rendimiento en comparación con los métodos existentes y reducir el tiempo para obtener resultados en la detección de biomarcadores clínicamente relevantes, incluidos proteínas secretadas, mutaciones puntuales y translocaciones cromosómicas.
Bio-Techne (NASDAQ: TECH)는 바이오마커 탐지 및 병리 실험실 작업 흐름 개선을 위한 RNAscope 기술의 발전을 발표했으며, 이는 2025년 USCAP 연례 회의에서 보스턴(3월 22-27)에서 발표될 예정입니다. 회사의 Advanced Cell Diagnostics 브랜드는 부스 #222에서 이 기술을 선보일 것입니다.
3월 25일 'RNAscope: Lightning Lunch and Learn' 세션 동안, 네 명의 저명한 병리학자들이 그들의 연구를 발표할 것입니다:
- Dr. Rohit Mehra는 신장 세포 암에서 TRIM63 mRNA의 마커에 대해 발표합니다.
- Dr. Vikram Deshpande는 간 종양을 위한 알부민 mRNA에 대해 발표합니다.
- Dr. Brooke Howitt는 부인과 종양에서의 점 돌연변이 탐지에 대해 발표합니다.
- Dr. Gregory Bean은 CRTC1/3::MAML2 전위에서의 mRNA 탐지에 대해 발표합니다.
이 발표들은 RNAscope가 기존 방법보다 성능을 개선하고 임상적으로 관련된 바이오마커, 즉 분비 단백질, 점 돌연변이 및 염색체 전위 탐지에서 결과 도출 시간을 단축할 수 있는 잠재력을 보여줄 것입니다.
Bio-Techne (NASDAQ: TECH) a annoncé des avancées dans sa technologie RNAscope pour la détection de biomarqueurs et l'amélioration des flux de travail en laboratoire de pathologie, qui seront présentées lors de la réunion annuelle USCAP 2025 à Boston (22-27 mars). La marque Advanced Cell Diagnostics de l'entreprise mettra en avant la technologie au stand n° 222.
Lors de la session 'RNAscope: Lightning Lunch and Learn' le 25 mars, quatre pathologistes de premier plan présenteront leurs recherches :
- Dr. Rohit Mehra sur l'ARNm TRIM63 comme marqueur dans le carcinome à cellules rénales
- Dr. Vikram Deshpande sur l'ARNm d'albumine pour les tumeurs hépatiques
- Dr. Brooke Howitt sur la détection des mutations ponctuelles dans les tumeurs gynécologiques
- Dr. Gregory Bean sur la détection de l'ARNm provenant des translocations CRTC1/3::MAML2
Les présentations démontreront le potentiel de RNAscope à améliorer les performances par rapport aux méthodes existantes et à réduire le temps de résultats dans la détection de biomarqueurs cliniquement pertinents, y compris les protéines sécrétées, les mutations ponctuelles et les translocations chromosomiques.
Bio-Techne (NASDAQ: TECH) hat Fortschritte in seiner RNAscope-Technologie zur Biomarkererkennung und zur Verbesserung des Arbeitsablaufs in Pathologielaboren angekündigt, die auf dem USCAP-Jahrestreffen 2025 in Boston (22.-27. März) präsentiert werden. Die Marke Advanced Cell Diagnostics des Unternehmens wird die Technologie am Stand Nr. 222 vorstellen.
Während der Sitzung 'RNAscope: Lightning Lunch and Learn' am 25. März werden vier führende Pathologen ihre Forschung präsentieren:
- Dr. Rohit Mehra über TRIM63 mRNA als Marker bei Nierenzellkarzinom
- Dr. Vikram Deshpande über Albumin mRNA bei Lebertumoren
- Dr. Brooke Howitt über die Erkennung von Punktmutationen in gynäkologischen Tumoren
- Dr. Gregory Bean über die Erkennung von mRNA aus CRTC1/3::MAML2-Translokationen
Die Präsentationen werden das Potenzial von RNAscope demonstrieren, die Leistung im Vergleich zu bestehenden Methoden zu verbessern und die Zeit bis zu den Ergebnissen bei der Erkennung klinisch relevanter Biomarker, einschließlich sekretierter Proteine, Punktmutationen und chromosomaler Translokationen, zu verkürzen.
- RNAscope technology demonstrates superior performance in biomarker detection compared to traditional methods
- Technology shows potential for improved diagnostic accuracy in multiple cancer types
- Validation of technology by leading pathologists from prestigious institutions
- Product is currently to research use only, not approved for diagnostic procedures
Leading pathologists will describe how they have used RNAscope technology to detect clinically relevant biomarkers, including secreted proteins, point mutations and chromosomal translocations, with the potential to improve performance over existing methods and reduce time to results. The session "RNAscope: Lightning Lunch and Learn" at noon on Tuesday, March 25, will highlight four pathologists describing their work using RNAscope technology:
- Dr. Rohit Mehra, Professor of Pathology at the University of
Michigan , will describe TRIM63 mRNA as a surrogate marker in translocation-associated renal cell carcinoma, as an option to traditional DNA FISH. - Dr. Vikram Deshpande, Professor of Pathology at Beth Israel Deaconess Medical Center, will detail how albumin mRNA can be a superior marker to secreted protein in primary and secondary liver tumors.
- Dr. Brooke Howitt, Associate Professor of Pathology at Stanford University, will present advances in the in situ detection of point mutations in molecularly defined gynecologic tumors.
- Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the identification of mucoepidermoid carcinomas and hidradenomas.
"We've made exciting advancements on in situ hybridization methods enabling novel applications in pathology laboratories," commented Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "This conference session highlights the frontier of clinical and translational research by leading pathologists using the latest RNAscope technologies for detecting the molecular underpinnings of disease."
For Research Use Only. Not intended for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-advances-in-the-detection-of-clinically-relevant-biomarkers-using-rnascope-technologies-at-the-2025-uscap-annual-meeting-302407635.html
SOURCE Bio-Techne Corporation
FAQ
What innovations will Bio-Techne (TECH) present at USCAP 2025 regarding RNAscope technology?
How does Bio-Techne's RNAscope technology improve liver tumor detection?
What are the key applications of TECH's RNAscope technology in gynecologic tumors?
When and where will Bio-Techne (TECH) present its RNAscope technology at USCAP 2025?
